Nilotinib and Paclitaxel for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Jun 2020: Trial registered, NCT04449549
  2. 24 Aug 2020: Trial started, NCT04449549

The trials

NCT04449549: Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

State
Under way
Phase
Phase 2
People
82 planned
Started
24 Aug 2020
Primary completion
2 Apr 2027
Arms
1
Results
None posted
  1. 29 Jun 2020: Trial registered
  2. 24 Aug 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.